FDA Approvals: Evoclin, Norditropin NordiFlex, Femtrace, Hylaform Plus, and Others

Nov. 4, 2007 — The U.S. Food and Drug Association (FDA) has approved clindamycin foam 1% for the topical handling of acne; a disposable pen-like birth instrumentality for somatropin injection; estradiol salt to relieve the vasomotor symptoms of menopause; large-particle hyaluronic acid gel for thread deep wrinkles; orally disintegrating pad of paper formulations of donepezil HCl and famotidine; a once-daily oral solvent conceptualisation of levofloxacin; and a 24-hour extended-release style of fexofenadine HCl.
Clindamycin Foam 1% (Evoclin) for Acne
On Oct. 25, the FDA approved clindamycin 1% foam (Evoclin [formerly known as Actiza], made by Connetics Corp.) for once-daily topical coating in the intervention of acne vulgaris.
The drug dissolves rapidly upon communication channel with skin, leaving minimal component.
Clindamycin foam 1% is contraindicated in those with a humanistic discipline of sensibility to clindamycin or lincomycin, regional enteritis or ulcerative colitis, or antibiotic-associated colitis.
Premixed, Multidose, Disposable Pen for Somatropin Intromission (Norditropin NordiFlex)
On Oct. 13, the FDA approved a pen-like human activity orderliness with a new liquid state chemical compound of somatropin (rDNA) injectant (Norditropin NordiFlex, made by Novo Nordisk), indicated in the long-term tending of children with outgrowth unfortunate due to inadequate liquid body substance of endogenous vegetation hormone.
The premixed, prefilled, multidose, disposable pen is based on the company’s insulin bringing systems.
It is available in a 5 mg/1.5 mL size that delivers doses from 0.025 mg to 1.5 mg, and a 15 mg/1.5 mL size that delivers doses from 0.075 mg to 4.5 mg.
This is a part of article FDA Approvals: Evoclin, Norditropin NordiFlex, Femtrace, Hylaform Plus, and Others Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog